Key facts
- Poclight Biotech’s last known valuation is $45.3M (Aug 2021).
- It has raised $23.7M; the latest was Later Stage VC in Jan 2026.
- Notable investors include Huatai Zijin Investment, Zhuzhou SAH Innovation & Entrepreneur Investment, Nanjing New Industry Investment Group, Jointown Investment, Junwei Venture — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Poclight Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Poclight Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Poclight Biotech
Provider of biotechnology services intended for diagnostic and monitoring purposes. The company leverages resonance energy transfer technology, patented one-step dry chemiluminescence immunoassay methods, freeze-dried microsphere development, and room-temperature storage capabilities, offering precise detection of small molecules and metabolic products while supporting applications in drug testing, food safety, livestock health, and environmental monitoring, enabling healthcare and industrial sectors to achieve accurate, cost-effective, and scalable diagnostic solutions that meet diverse market needs and promote global health standards.
- Sector
- Healthcare
- HQ
- Nanjing, China
- Founded
- 2019
- Employees
- 100
- Website
- puguangbio.com/
- Ownership
- Privately Held (backing)
Poclight Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Poclight Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Poclight Biotech in its N-PORT filings yet. We sweep new filings monthly.